Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Histidine 6.55 is a major determinant of ligand biased signaling in dopamine D2L receptor

Nuska Tschammer, Stefan Bollinger, Terry Kenakin and Peter Gmeiner
Molecular Pharmacology December 16, 2010, mol.110.068106; DOI: https://doi.org/10.1124/mol.110.068106
Nuska Tschammer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Bollinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terry Kenakin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Gmeiner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

In our previous studies, we demonstrated that the mutation of His3936.55 to alanine results in an increased affinity of 1,4-disubstituted phenylpiperazines to the dopamine D2L receptor. This change most likely accounts for the reduced steric hindrance in this part of the binding pocket. In this work, we investigated the role of the steric hindrance imposed by the residue His3936.55 for the receptor activation modulated by 1,4-DAPs. Site-directed mutagenesis and ligand modifications were used to probe the structural basis of ligand efficacy. The operational model of agonism was employed to quantify the ligand bias between the ability of compounds to inhibit cAMP accumulation and to stimulate ERK1/2 phosphorylation. Whereas substantial ligand biased signaling was observed for the D2L wild type receptor, an overall increase in agonism was observed for the D2L His3936.55Ala mutant without noteworthy functional selectivity. Targeted chemical modification of the phenylpiperazine moiety at the site of its interaction with the residue His3936.55 led to the functionally selective ligand FAUC350 that has distinct signaling profiles toward adenylyl cyclase and ERK1/2. FAUC350 behaves as an antagonist in the inhibition of cAMP accumulation and as a partial agonist in the stimulation of ERK1/2 phosphorylation (efficacy = 55%). Overall, the residue His3936.55 and proximate molecular substructures of receptor ligands were identified to be crucial for multidimensional ligand efficacy.

  • Dopamine
  • Gi family
  • Adenylyl cyclases
  • MAP Kinase
  • Mutagenesis/Chimeric approaches
  • Anti-psychotics
  • Received August 9, 2010.
  • Revision received December 16, 2010.
  • Accepted December 16, 2010.
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 103 (2)
Molecular Pharmacology
Vol. 103, Issue 2
1 Feb 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Histidine 6.55 is a major determinant of ligand biased signaling in dopamine D2L receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Histidine 6.55 is a major determinant of ligand biased signaling in dopamine D2L receptor

Nuska Tschammer, Stefan Bollinger, Terry Kenakin and Peter Gmeiner
Molecular Pharmacology December 16, 2010, mol.110.068106; DOI: https://doi.org/10.1124/mol.110.068106

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Histidine 6.55 is a major determinant of ligand biased signaling in dopamine D2L receptor

Nuska Tschammer, Stefan Bollinger, Terry Kenakin and Peter Gmeiner
Molecular Pharmacology December 16, 2010, mol.110.068106; DOI: https://doi.org/10.1124/mol.110.068106
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics